All In Biotech

Drug Trial Radar · NCT01648777

Catheter Outcomes With Sternotomy Cardiac Operated

Cicatricial Analgesia Catheters Outcome on Bronchopulmonary Infection Number With Sternotomy Cardiac Operated

Last checked: Nov 19, 2026Latest source record: Apr 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,502 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,502

Actual

Start

Mar 2012

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Baxter Healthcare Corporation; WYM France; Abbott
First posted
Jul 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pneumonia occurs frequently in patients undergoing cardiac surgery and allows to increase their mortality. While chest physical therapy plays a crucial role to prevent postoperative pneumoniae, painful mobilization of the sternum after sternotomy limits chest physical therapy. The continuous local anesthetic infusion by multiperforated catheter decreases sternum pain. Because of this optimal pain management, early chest physical therapy could be more efficient and could contribute to decrease the rate of pneumonia. The aim of this study is to test if management of sternotomy pain using continuous local anesthetic infusion by multiperforated catheter may contribute to decrease the rate of perioperative pneumonia.

Conditions

  • Pneumonia
  • Cardiac Surgery
  • Multiperforated Catheter
  • Analgesia
  • Critical Care Medicine

Interventions

  • L bupivacaineDevice

    L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00

  • placeboDrug

    * Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml * Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of post-operative pneumonia in hospitalTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pitié salpetrière Hospital

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.